Literature DB >> 9787738

Cardiac transplantation for end-stage congenital heart defects: the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team.

G Speziali1, D J Driscoll, G K Danielson, P R Julsrud, C J Porter, J A Dearani, R C Daly, C G McGregor.   

Abstract

OBJECTIVE: To review the outcome of cardiac transplantation undertaken in patients with congenital heart defects.
MATERIAL AND METHODS: Between November 1991 and March 1998 at our institution, cardiac transplantation was performed in 16 patients with congenital heart disease (age range, 3 to 57 years; mean, 26.1). Preoperative diagnoses included univentricular heart (N = 4); complete transposition of the great arteries (N = 3); Ebstein's anomaly (N = 2); tetralogy of Fallot (N = 2); levotransposition (N = 2); dextrocardia, corrected transposition, ventricular and atrial septal defects, and pulmonary stenosis (N = 1); double-outlet right ventricle (N = 1); and hypertrophic obstructive cardiomyopathy (N = 1). All patients had undergone from one to five previous palliative operations.
RESULTS: Four patients required permanent pacemaker implantation during the first month postoperatively because of bradycardia; more than 2 years later, another patient required a permanent pacemaker because of sick sinus syndrome. In addition, one patient had an automatic implantable cardioverter-defibrillator. Three patients required reconstruction of cardiovascular structures with use of prosthetic material (Teflon patches or donor tissue) at the time of cardiac transplantation. Actuarial 1-, 2-, and 5-year survival was 86.2 +/- 9.1%. During the first year after transplantation, two deaths occurred--one at 41 days of putative vascular rejection and the second at 60 days of severe cellular rejection. All other patients are alive and functionally rehabilitated; the mean follow-up period has been 26.1 months (range, 2 to 89.6).
CONCLUSION: Cardiac transplantation for patients with congenital heart disease can be accomplished with a low perioperative mortality and an excellent medium-term survival despite the challenges presented by the technical difficulties during invasive diagnostic procedures and at operation and the need for adherence to long-term multiple-drug therapy in this patient population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787738     DOI: 10.4065/73.10.923

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

1.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions.

Authors:  Candice K Silversides; Omid Salehian; Erwin Oechslin; Markus Schwerzmann; Isabelle Vonder Muhll; Paul Khairy; Eric Horlick; Mike Landzberg; Folkert Meijboom; Carole Warnes; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

2.  Overview of adult congenital heart transplants.

Authors:  Roosevelt Bryant; David Morales
Journal:  Ann Cardiothorac Surg       Date:  2018-01

3.  Left ventricular assist device implantation in a patient with congenitally corrected transposition of the great arteries.

Authors:  Igor D Gregoric; Roman Kosir; Frank W Smart; Gregory N Messner; Vijay S Patel; Saverio La Francesca; Roberto D Cervera; O H Frazier
Journal:  Tex Heart Inst J       Date:  2005

Review 4.  Heart transplantation for adults with congenital heart disease: current status and future prospects.

Authors:  Hikaru Matsuda; Hajime Ichikawa; Takayoshi Ueno; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-04-24

5.  Organ allocation in adults with congenital heart disease listed for heart transplant: impact of ventricular assist devices.

Authors:  Jill M Gelow; Howard K Song; Joseph B Weiss; James O Mudd; Craig S Broberg
Journal:  J Heart Lung Transplant       Date:  2013-08-06       Impact factor: 10.247

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.